Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons
Phase: NA
Conditions: HIV Infections, Staphylococcal Infections
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
 
 
Prospective Study on the Incidence, Predictors, and Characteristics of 
Methicillin-Resistant Staphylococcus aureus Infections and a 
Randomized, Double-Blind Study on Decolonization Procedures for 
Prevention of MRSA Infections among HIV-infected Persons   
 
 
RV 210 
July 2, 2014 
Version 7.0 
 
 
 
Principal Investigator 
Brian Agan, MD 
Infectious Disease Clinical Research Program 
Uniformed Services University of the Health Sciences (USUHS) 
Bethesda, MD 20814 
 
 
Sponsor 
 
Infectious Disease Clinical Research Program (IDCRP) 
National Institutes of Health (NIH) 
National Institute of Allergy and Infectious Disease (NIAID) 
U.S. Military HIV Research Program (USMHRP) 
 
 
 
 
FWA# 00002342 (NMCSD) 
FWA# 00004092 (SAMMC) 
FWA# 00017749 (WRNMMC) 
FWA# 00001750 (WHASC) 
FWA# 0006001 (NMCP) 
                                                          
 
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
2 
 
TABLE OF CONTENTS 
 
LIST OF ABBREVIATIONS ..................................................................................................5 
I. PRECIS ..................................................................................................................................6 
II. STUDY SITES ......................................................................................................................7 
III. OBJECTIVES .....................................................................................................................8 
3.1 Primary Objectives ......................................................................................................... 8 
3.2 Secondary Objectives ..................................................................................................... 8 
IV.  BACKGROUND AND SIGNIFICANCE ........................................................................8 
V. RESEARCH DESIGN .......................................................................................................11 
5.1 General Approach ........................................................................................................ 11 
5.2 Subject Population ........................................................................................................ 13 
5.3 Inclusion Criteria .......................................................................................................... 13 
5.4 Exclusion Criteria ......................................................................................................... 13 
VI. METHODS ........................................................................................................................13 
6.1 Pre-enrollment .............................................................................................................. 14 
6.2 Enrollment ..................................................................................................................... 14 
6.3 Active Surveillance & Clinic Assessments.................................................................. 14 
6.4 Details of Laboratory Studies ...................................................................................... 18 
6.5 Clinical Outcomes ......................................................................................................... 19 
6.6 Laboratory Outcomes .................................................................................................. 19 
6.7 Randomization Procedures .......................................................................................... 19 
6.8 Study Drug .................................................................................................................... 20 
6.9 Adverse Event Reporting ............................................................................................. 20 
6.9.1 Grading Adverse Events for Severity ...................................................................... 21 
6.9.2 Relatedness of Adverse Events to the Study Drugs ................................................ 21 
6.10 Termination ................................................................................................................. 22 
VII. STATISTICAL ANALYSES .........................................................................................23 
VIII.  DATA ENTRY AND ANALYSES ..............................................................................26 
IX.  STORING AND DISSEMINATION OF DATA ..........................................................27 
X.  FACILITIES TO BE USED .............................................................................................28 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
3 
10.1 Laboratory .................................................................................................................. 28 
10.2 Clinical ......................................................................................................................... 28 
10.3 Planning and Use for Storage of Biological Specimens ........................................... 29 
XI. TIME REQUIRED TO COMPLETE ............................................................................29 
XII. NUMBER OF SUBJECTS TO BE STUDIED .............................................................29 
XIII. NUMBER OF CHARTS TO BE REVIEWED ...........................................................29 
XIV.  FUNDING IMPLICATIONS ......................................................................................29 
XV.   DATE PREPARED .......................................................................................................29 
XVI. BIBLIOGRAPHY ..........................................................................................................31 
XVII.   APPENDICES ............................................................................................................34 
APPENDIX A: ADVERTISING FLIER .......................................................................... 35 
APPENDIX B: BUDGET ................................................................................................... 36 
APPENDIX C:  ROLES AND RESPONSIBILITIES .................................................... 37 
APPENDIX D: SCHEDULE OF EVENTS ...................................................................... 38 
XVIII.  ATTACHMENTS ......................................................................................................39 
ATTACHMENT A: TOXICITY TABLE ........................................................................ 40 
ATTACHMENT B: INFORMED CONSENT................................................................. 41 
ATTACHMENT C: REQUIREMENTS FOR STUDIES INVOLVING HUMAN 
PATIENTS .......................................................................................................................... 42 
18.C.1 
Study Conduct ..................................................................................................... 42 
18.C.2 
Subject Confidentiality ....................................................................................... 42 
18.C.3 
Subject Compensation ........................................................................................ 42 
18.C.4 
Medical Monitors ................................................................................................ 42 
18.C.5 
Experimental Procedure(s) ................................................................................ 43 
18.C.6 
Risks ..................................................................................................................... 43 
18.C.7 
Benefits ................................................................................................................. 44 
18.C.8 
Informed Consent ............................................................................................... 44 
18.C.9 
Institutional Review Board or Ethical Review Committee (IRB or ERC) .... 44 
18.C.10 
Protocol Amendments and Emergency Deviations ...................................... 45 
18.C.11 
Monitoring of Study sites by the Sponsor’s Representative ........................ 45 
18.C.12 
Case Report Forms and Study Records ......................................................... 46 
18.C.13 
Laboratory Certification and Normal Ranges .............................................. 46 
18.C.14 
Drug Accountability ........................................................................................ 46 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
4 
18.C.15 
Record Retention ............................................................................................. 46 
18.C.16 
Inspection of Records ...................................................................................... 46 
ATTACHMENT D: PACKAGE INSERTS ..................................................................... 47 
ATTACHMENT E: PROTOCOL SIGNATURE PAGE ............................................... 48 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
5 
LIST OF ABBREVIATIONS 
 
AE 
Adverse Event 
CD4 
Cluster of differentiation antigen 4 
CDC 
Centers for Disease Control and Prevention 
CFR 
Code of Federal Regulations 
CRF 
Case Report Form 
CV 
Curriculum Vitae 
DCC 
Data Coordination Center 
DNA PCR 
Deoxyribonucleic acid polymerase chain reaction 
EC 
Ethics Committee 
EIA 
Enzyme Immunoassay 
ELISA 
Enzyme–linked Immunosorbent Assay 
ERC 
Ethical Review Committee 
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HAART 
Highly Active Antiretroviral Therapy 
HIV 
Human Immunodeficiency Virus 
HJF 
Henry M. Jackson Foundation 
HSRRB 
Human Subjects Research Review Board 
HURC 
Human Use Review Committee 
ICH 
International Conference on Harmonization 
IDCRP 
Infectious Disease Clinical Research Program 
IRB 
Institutional Review Board 
MRSA 
Methicillin-resistant Staphylococcus aureus 
MSM 
men who have sex with men 
MSSA 
Methicillin-sensitive Staphylococcus aureus  
NIAID 
National Institute of Allergy and Infectious Diseases 
NIH 
National Institutes of Health 
NMCP 
Naval Medical Center Portsmouth 
NMCSD 
Naval Medical Center San Diego 
NOS 
Not otherwise specified 
OHRP 
Office of Human Research Protections 
OTSG 
Office of the Surgeon General 
PI 
Principal Investigator 
PIN 
Participant Identification Number 
PVL 
Panton-Valentine Leukocidin 
RCHSPB 
Regulatory Compliance and Human Subjects Protection 
Branch 
RNA-PCR 
Ribonucleic acid polymerase chain reaction 
SAE 
Serious Adverse Event 
SAMHS 
San Antonio Military Health System 
SAMMC 
San Antonio Military Medical Center 
SOP 
Standard Operating Procedure 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
6 
SPI 
Site Principal Investigator 
TMP/SMX 
Trimethoprim-sulfamethoxazole 
USMHRP 
U.S. Military HIV Research Program 
USUHS 
Uniformed Services University of the Health Sciences 
WHASC 
Wilford Hall Ambulatory Surgical Center 
WRNMMC 
Walter Reed National Military Medical Center at Bethesda 
 
I. PRECIS 
Methicillin-resistant Staphylococcus aureus (MRSA) infections have dramatically 
increased over the past decade with novel community-acquired isolates occurring 
worldwide [1, 2].  Despite that many of these community-acquired MRSA infections are 
skin or soft tissue infections occurring in young, otherwise healthy individuals, they have 
been associated with high hospitalization rates and the potential for severe complications 
[1, 3-5].  The most common risk factors for community-acquired MRSA infections among 
the general population have been prior antibiotic use, prior hospitalization, injection drug 
use, and contact with a person with MRSA-infection [6-10].   
Human immunodeficiency virus (HIV) infection is also a known risk factor for 
both MRSA colonization and infection [7, 8, 11].  To date, only retrospective studies have 
examined the incidence rates and the predictors for community-acquired MRSA among 
HIV-infected persons [7, 12, 13].  Furthermore, whether HIV patients should be screened 
routinely for MRSA carriage and whether decolonization procedures, with 
hexachlorophene (also known as pHisoHex® soaps) soaps and nasal mupirocin, should be 
instituted remains unknown as there are no formal guidelines or prospective studies 
addressing these questions.   
This study will prospectively evaluate the prevalence and incidence (over a two 
year period) of MRSA colonization and infection among HIV-infected military 
beneficiaries to determine predictors for the development of MRSA colonization and 
infection.  This study will also investigate the utility of decolonization procedures for 
clearance of MRSA carriage and prevention of MRSA infections.  The molecular 
characteristics and the antimicrobial sensitivities of isolates in this population will be 
determined. 
Additionally, medical records of HIV-infected patients seen at the HIV clinic at 
NMCSD will be evaluated to determine the incidence and clinical features of MRSA 
infections among this population.  This is an ongoing evaluation (IDCRP-049) since 2006 
(date of study initiation) that utilizes previously collected information (since 1993 until 
March 1, 2011) found within the patients’ medical records, and does not require contact 
with the patients and does not collect any new information.  The purpose of this study is to 
determine the incidence of MRSA among a total HIV population.  This ongoing chart 
review is merged into this prospective study as both studies aim to evaluate the impact of 
MRSA infections in HIV-infected persons. 
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
7 
II. STUDY SITES 
 
Sponsor 
Infectious Disease Clinical Research Program (IDCRP) 
Uniformed Services University of the Health Sciences (USUHS) 
11300 Rockville Pike, Suite 1201 
Rockville, MD 20852 
 
National Institutes of Health (NIH) 
National Institute of Allergy and Infectious Disease (NIAID) 
6700-B Rockledge Drive 
Bethesda, MD  20892-5138 
Monitoring 
Team 
Regulatory Compliance and Human Subjects Protection Branch 
(RCHSPB) 
6700-B Rockledge Drive, MSC 7609 
Bethesda, MD 20892-5138 
Laboratory  
San Antonio Military Medical Center 
3551 Roger Brooke Dr, MCHE-MDI 
JBSA-Fort Sam Houston, TX 78234 
Phone (210) 916-3859 
 
 
Naval Medical Center San Diego (NMCSD) 
Infectious Disease Division 
34800 Bob Wilson Drive, Suite 201 
San Diego, CA  92134-1201 
Phone: (619) 532-7475     Fax: (619) 532-7478 
Walter Reed National Military Medical Center (WRNMMC) 
Infectious Disease Clinic 
8960 Brown Drive 
Building 7, 1st Floor 
Bethesda, MD 20889 
Phone: (301) 295-6400     Fax: (301) 295-2994 
Wilford Hall Ambulatory Surgical Center (WHASC) 
Infectious Disease Department 
2200 Bergquist Drive, Suite 1 
Lackland AFB, San Antonio, TX 78236 
Phone: (210) 292-2583     Fax: (210) 675-0173 
San Antonio Military Medical Center (SAMMC) 
3551 Roger Brooke Drive, MCHE-MDI 
JBSA-Fort Sam Houston, Tx 78234 
Phone: (210) 916-4355  
Naval Medical Center Portsmouth (NMCP) 
620 John Paul Jones Circle 
Portsmouth, Virginia 23708 
Phone: (757) 953-5199 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
8 
 
 
III. OBJECTIVES 
 
3.1 Primary Objectives 
 
To evaluate the effectiveness of decolonization procedures with application of 
hexachlorophene (pHisoHex®) soaps  and nasal mupirocin (Bactroban®) compared to a 
placebo soap and nasal ointment which have no antibacterial activity among patients found 
to be colonized with MRSA in the prevention of future colonization with MRSA.  As a 
secondary part of this objective, we will examine the impact of decolonization procedures 
on both infections with MRSA and soft tissue infections.  In addition, as a sub-analysis to 
the primary objective, we will evaluate the impact of decolonization among unique 
randomizations (persons with first time MRSA colonization and randomization during the 
study). 
 
3.2 Secondary Objectives 
 
a. To determine the prevalence and incidence of MRSA colonization of the nares, throat, 
perirectal, axilla, and groin areas among HIV infected patients and to study changes in the 
colonization rates over time. 
 
b. To determine the predictors of MRSA colonization and infection among HIV-infected 
persons including examination of demographics, sexual activity, hygienic practices, drug 
use, antibiotic and antiretroviral medications, sexually transmitted diseases, and HIV 
control. 
 
c. To evaluate the change in CD4 counts and HIV viral loads during the time of a MRSA 
or soft tissue infection. 
 
d. To characterize the molecular characteristics and the antimicrobial sensitivities of 
MRSA isolates in this population. 
 
e. To continue the previous retrospective study of MRSA infections among HIV-infected 
persons to examine the incidence of and describe the clinical features of MRSA infections 
and their response to treatment among HIV-infected patients seen within the HIV clinic at 
NMCSD.  This study also will continue to compare those with and without MRSA 
infections in terms of demographic data, HIV viral loads, CD4 counts, and use of 
medications including antiretroviral and antimicrobial agents. 
 
IV.  BACKGROUND AND SIGNIFICANCE 
 
MRSA was first recognized in 1961 and subsequently became a frequent cause of 
infections within the hospital setting.  The first community-acquired MRSA infections 
occurred in the early 1980s.  Within the past several years, the number of community-
acquired MRSA cases has dramatically increased with incidence rates of 18 to 26 cases per 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
9 
100,000 persons [1, 2].  In addition to individual cases, numerous outbreaks have occurred 
among prison inmates, athletes, military trainees, and men who have sex with men (MSM) 
[14-18].  
Patients presenting with community-acquired MRSA infections typically present 
with skin or soft tissue infections such as folliculitis, furuncles, carbuncles, abscesses, or 
cellulitis [1, 7].  Despite that most of these infections occur in young, otherwise healthy 
individuals, community-acquired MRSA infections have led to a high hospitalization rate 
with up to 25% requiring admission for the management of the MRSA infection [1].  
Severe, life-threatening cases have been described involving community-acquired 
MRSA infections including cases of necrotizing fasciitis; although there were no deaths in 
this series, significant morbidity was noted [3].  Cases of community-acquired MRSA soft 
tissue infections complicated by endocarditis and septic pulmonary emboli have also been 
reported, as well as by pyomyositis and toxic shock–like syndrome [4-6].  Several cases of 
necrotizing pneumonia have also been reported, especially among children [19].  
The reasons that community-acquired MRSA strains cause severe infections remain 
unclear.  Type IV SCCmec type, Panton-Valentine leukocidin (PVL)-positive isolates are 
characteristic of community-acquired MRSA.  The presence of the PVL genes, which 
encode for a cytotoxin associated with polymorphonuclear leukocyte lysis and tissue 
necrosis, has been linked to cases of community-acquired MRSA soft tissue infections and 
pneumonia [19-21].  The most common clone of community acquired MRSA is USA 300, 
and this itself is likely a more virulent strain [22].  In addition, a study by Voyich and 
associates demonstrated that community-acquired MRSA isolates were more resistant to 
killing by neutrophils and caused greater host cell lysis than nosocomial strains in mouse 
models.  This group is also examining a variety of genes that may help community-
acquired MRSA strains avoid destruction by neutrophils [23].  Finally, studies have 
suggested that community-acquired MRSA may exhibit faster doubling times than 
nosocomial strains [24].  
 
The most common risk factors for community-acquired MRSA infections among 
the general population are prior antibiotic use, prior hospitalization, underlying medical 
conditions including HIV infection, injection drug use, and contact with a person with 
MRSA-infection or colonization; similar risk factors are cited for those colonized with 
MRSA [7-10].  A study among military personnel, who resided in close proximity to one 
another, found that risk factors for MRSA were having a roommate with history of a soft 
tissue infection and having a family member or friend who worked in the healthcare setting 
[10].  A study among football players found that team members with frequent skin 
abrasions, such as linemen, were at highest risk of infection [18].  Finally, population-
based studies have shown that young age and racial minorities may have a heightened risk 
[1, 20]. 
HIV infection is a known risk factor for both MRSA colonization and infection [7, 
8, 11].  A recent study showed that community-acquired MRSA increased six-fold among 
HIV-infected persons during the years 2000 to 2003 [7].  Risk factors for community-
acquired MRSA among HIV-infected patients cited in the literature include a history of 
MSM or intravenous drug use as the patient’s HIV transmission risk factor, a low current 
CD4 count, high HIV viral load, and the absence of trimethoprim-sulfamethoxazole 
(TMP/SMX) prophylaxis [7].  Other studies found an association with exposure to public 
hot tubs/saunas, having a sex partner with a skin infection, and prior beta-lactam 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
10 
antibiotics [13, 25].  Colonization with MRSA among HIV infected persons has been 
linked to low CD4 count (<100 cells/mm3), lack of TMP/SMX prophylaxis, recent 
antibiotic use, and hospitalizations [26, 27]. 
A retrospective case-control study was performed including the years of 1993-2005 
among 425 HIV patients seen at the Naval Medical Center San Diego (NMCSD), of 
whom, 25 (5.9%) patients were found to be infected with community-acquired MRSA.  All 
cases occurred after 2002, with a 17-fold increase from 2003 to 2005 (Chi-square test of 
trend 15.7, p<0.001).  The annual incidence during the year 2005 among our HIV patients 
was 40 cases/1000 person-years compared to 2.28 cases/1000 person-years (or 741 
cases/325,000) among HIV-negative persons (18-fold higher rate).  In the univariate 
analyses, lower current CD4 count, CDC stage C vs. A, history of syphilis, and exposure to 
beta-lactam antibiotics in the past year were predictive of MRSA.  In the multivariate 
model, history of syphilis and exposure to beta-lactam antibiotics remained as significant 
predictors [12]. 
Most MRSA infections among HIV-infected patients involve the soft-tissues and 
present as folliculitis, furuncles, carbuncles, abscesses, cellulitis, or necrotizing fasciitis 
[7].  HIV-infected persons presenting with a history of a “bug bite” or soft tissue infection 
should be evaluated for MRSA.  Treatment of MRSA infections has not been standardized 
and the optimal therapeutic regimen remains unknown.  Of note, antibiotic resistance for 
community-acquired strains is typically less than for nosocomial isolates due to reduced 
antibiotic pressures and due to the smaller chromosomal cassette.  However, increasing 
resistance to antibiotics has been noted among community-acquired isolates, including 
rising rates of clindamycin resistance [28, 29]. 
 
Whether HIV patients should be screened routinely for MRSA carriage and 
whether decolonization procedures, with hexachlorophene (pHisoHex®) soaps and nasal 
mupirocin (Bactroban®), should be instituted remains unknown as there are no formal 
guidelines addressing these questions.  Regarding screening for MRSA carriage, studies 
among HIV patients have suggested that high risk sexual activities and potentially peri-
rectal carriage of MRSA may be important in the epidemiology of CA-MRSA infections.  
Although, a recent study showed limited use of perianal cultures for MRSAs screening, 
this study was solely among patients at a rehabilitation unit [30a], rather than HIV patients 
who likely have divergent risk factors and routes of MRSA transmission.  A recently 
presented abstract in HIV patients showed a poor correlation between MRSA nares 
carriage and MRSA infection [30b], hence we will evaluate the possible additive benefit of 
perianal and throat cultures in this cohort.  Our study will examine nares, throat, axilla, 
groin, and perirectal surveillance cultures for MRSA among HIV patients.  
Although there are no formal recommendations for the use of TMP/SMX to 
prevent MRSA infections among HIV-infected patients, those patients requiring this 
antibiotic for other indications (e.g., Pneumocystis carinii pneumonia or Toxoplasma 
prophylaxis) have lower rates of MRSA infection.  Given the higher rates of community-
acquired MRSA among HIV-infected patients and that this group may have a propensity 
towards recurrent infections [5], formulating preventive strategies would be useful. 
The use of mupirocin nasal ointment (also known as Bactroban®) and 
hexachlorophene (pHisoHex®) soaps has been studied both during MRSA outbreaks and 
to decrease colonization and infection rates in the healthcare setting with favorable results 
[31-37].  The medications have a low rate of side effects and good efficacy [38, 39].  

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
11 
Although reported in the literature, the risk for inducing resistance to mupirocin by its use 
for MRSA decolonization is low even in a study applying the medication for seven 
consecutive years [35, 40]. 
 
We propose to prospectively study the prevalence and incidence over a two year 
period of MRSA colonization and infection among HIV-infected military beneficiaries, to 
determine predictors among this population for the development of MRSA colonization 
and infection and to investigate the utility of decolonization procedures in this group.  In 
addition, we will evaluate the molecular characteristics and the antimicrobial sensitivities 
of isolates in this population.   
We also propose to continue collecting retrospective data among HIV-infected 
patients at NMCSD, which has low risk and does not involve patient contact or further 
testing.  The importance of this work is that more data regarding the risk factors of MRSA 
infections in this population may be useful for developing future preventive strategies.  
This is an ongoing study (previously IDCRP-049) that has been following HIV patients at 
this site since January 24, 2006 [45, 46].  Data collected on HIV patients will be 
retrospectively captured since 1993 or the date of the first HIV positive test, whichever is 
later.  We will continue to evaluate the patients for MRSA events until March 1, 2011.  
Only existing data will be used for this study; no information collected after March 1, 2011 
will be used for the retrospective study. 
 
 
V. RESEARCH DESIGN 
 
5.1 General Approach  
 
This is a prospective, randomized, double-blind study examining the incidence and 
risk factors for MRSA colonization and infection among HIV-infected persons and the 
efficacy of decolonization procedures of mupirocin (Bactroban®) nasal ointment and 
hexachlorophene (pHisoHex®) soaps compared to a placebo nasal ointment and body 
soap.  Inclusion criteria include adult (>18 years) HIV-positive patients; exclusion criteria 
include the presence of a known allergy to mupirocin (Bactroban®) nasal ointment or 
hexachlorophene (pHisoHex®) soaps, pregnant or breastfeeding females, age <18 years, 
persons who are healthcare providers with direct patient contact, and inability to participate 
in study for its two year duration.  A history of MRSA infection or colonization is not an 
exclusion criterion for this study.  Patients will be offered enrollment into the study at the 
time of presentation to the HIV clinic for routine care by their primary care physician 
and/or a study investigator.  General Institutional Review Board (IRB) approved 
advertisement posters about the study will be posted in each clinic. 
 
After signing the informed consent which includes a HIPAA form, the patient will 
be registered with the Data Coordination Center (DCC) and receive a participant 
identification number (PIN).  A patient will be assigned a PIN centrally once the patient 
agrees to participate in a Infectious Disease Clinical Research Program (IDCRP) study.  If 
a patient agrees to participate in other IDCRP studies, this same PIN will be used to link 
that patient to these other studies.  The patient will also be assigned a subject identification 
number unique to the patient and this study.  
 
Patients will then undergo swabs for determining colonization of MRSA and will 
fill out a questionnaire containing data regarding demographics, sexual activities, 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
12 
substance use, medication use, history of soft tissue infections, and potential risk factors 
for MRSA.  Study coordinators will review the patient’s medical record for data regarding 
medical history.  Patients will have repeated swabs, questionnaires, and review of their 
medical records every six months (+/- 2 months) during the two year study enrollment.   
The trial will be a randomized, double-blinded study. Patients found to have a 
positive culture for MRSA colonization will be randomized in a 1:1 fashion to mupirocin 
(Bactroban®) nasal ointment plus hexachlorophene (pHisoHex®) soap for seven days or to 
a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial 
activity for seven days; since there is no standard therapy recommended in the guidelines 
for MRSA management for MRSA colonization, patients in the latter arm will receive 
placebos with no specific antimicrobial activity.  In this design, we will ascertain if 
treatment for MRSA decolonization of this patient population is warranted or not.  After 
completion of these topical medications, patients will complete a questionnaire to ascertain 
their adherence to these medications.  Patients found to be colonized with MRSA and who 
reside locally (within driving distance) to the medical treatment facility will have repeat 
swabs (five swabs from sites listed above every four weeks (+/- 7 days) after any positive 
colonization cultures over the subsequent six month time period.  These cultures will assist 
in determining if the decolonization medications were successful at eradicating the carriage 
of MRSA.  Patients will receive one treatment course of either mupirocin (Bactroban®) 
nasal ointment plus hexachlorophene (pHisoHex®) soap for seven days or a placebo nasal 
ointment (white petroleum) and a placebo body soap with no antimicrobial activity for 
seven days.  Patients who are initially found to be negative for MRSA on screening swabs 
will be re-evaluated in six months (+/- 2 months).   
Patients who develop a soft tissue infection or any infection thought to be 
secondary to MRSA will be evaluated in the HIV clinic and will undergo wound cultures 
and repeated screening for MRSA colonization.  CD4 counts and an HIV viral load will be 
obtained at the time of infection.  Patient questionnaires and source documents will be 
completed for patients experiencing a soft tissue infection or MRSA infection.  
 
Cultures (from colonization sampling and wound cultures) which are positive for 
MRSA or MSSA at the local medical treatment facilities laboratories will be sent to the 
San Antonio Military Medical Center (SAMMC) laboratory for confirmation of MRSA, 
antibiotic susceptibility testing, and molecular analysis.   
 
We also propose to continue to review the charts (IDCRP-049) of all HIV-infected 
patients within the HIV clinic at NMCSD.  We will review all patients’ demographics, 
CDC stage, current CD4 counts, CD4 nadir, current HIV viral loads and medication use 
including antiretroviral and antimicrobial medications.  We will also identify those patients 
who were diagnosed with MRSA infection during the time they were infected with HIV.  
Patients charts in the HIV clinic will be reviewed from 1 January 1993 (the beginning of 
CHCS) or the data of HIV positivity (whichever is later) through 1 March 2011 in an 
ongoing fashion.  Among patients with MRSA, the following data will be collected from 
the charts and from CHCS: age, sex, race, years of HIV infection, CDC stage, CD4 count 
nadir, CD4 current value, current HIV viral load, medication use including antiretroviral 
and antimicrobial medications, antibiotics for MRSA, time of MRSA infection, type of 
MRSA infection, CD4 and viral load counts around the time of MRSA diagnosis, type of 
treatment, whether or not they were hospitalized and for how long, duration of the MRSA 
infection, any MRSA relapses, risk factors for MRSA, HSV2 serology, RPR serology, 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
13 
GC/Chlamydia testing, and any antibiotics used during the previous two years.  Data will 
be entered into a Microsoft Excel file without personal identifiers for analyses.  Datasets 
from the prospective RV210 study and this retrospective study will be maintained in 
separate databases since study populations will be diverse, however linkage between 
datasets will be possible through linking identifiers.   
  
5.2 Subject Population 
 
 
The study population will consist of those volunteers from the HIV clinics at the 
participating military HIV treatment centers including NMCSD, WRNMMC, SAMHS, 
and NMCP in their respective catchment areas.  Each clinic has approximately 500 HIV-
positive patients at any one time.  Since all adult HIV patients are eligible who do not have 
allergies to the agents utilized in this study (mupirocin (Bactroban®) nasal ointment or 
hexachlorophene (pHisoHex®) soaps), who are not healthcare workers with direct patient 
contact, and who are not pregnant or breastfeeding, over 95% of clinic patients will be 
eligible for enrollment.  A history of prior MRSA colonization and/or infection does not 
exclude entry into this study.  The total population of the study will be 550 participants.  If 
approximately 10-15% of participants carry the bacteria MRSA, then approximately 38 
patients will receive topical antibacterial treatment and the other 38 will receive placebo.  
Enrollment will be on a continuous basis until 550 participants have been enrolled.  The 
number of subjects per site will vary.  The San Antonio Military Medical Center will only 
enroll patients that reside locally to their medical treatment facility.  For the retrospective 
cohort, the study population will consist of all HIV patients who are 18 years or older and 
followed in the NMCSD HIV clinic. 
 
5.3 Inclusion Criteria  
 
1. Adults (≥18 years of age) who are HIV positive by a reactive screening (ELISA, EIA) 
and a confirmatory test (Western blot) and who are able to attend the study visits which are 
every 6 months (+/- 2 months), at the minimum. 
 
5.4 Exclusion Criteria 
  
1. Known allergy to mupirocin (Bactroban®) nasal ointment or hexachlorophene 
(pHisoHex®) soaps or constituents of these products. 
2. Age less than 18 years. 
3. Inability to remain in the study for the two year duration. 
4. Pregnant or breastfeeding females. 
5. Females who intend to become pregnant during the two year study time period. 
6. Persons who are healthcare providers with direct patient contact. 
 
For the study evaluating medical records for the incidence and risk factors of MRSA 
infections, all adult HIV patients in the NMCSD HIV clinic will be evaluated. 
 
VI. METHODS 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
14 
6.1 Pre-enrollment 
 
During regularly scheduled medical visits, HIV-positive patients will be offered 
participation in this research study.  Eligibility requirements will be assessed through 
verbal discussion.  IRB approved advertisement posters about the study will be posted in 
the clinic.  Supplies for the study and subsequent data collection will be organized.  Study 
staff jobs will be allocated to allow for optimal study performance during enrollment and 
data collection.  The case report forms (CRFs) will be created to ensure consistent 
reporting and time efficiency.  
 
6.2 Enrollment 
 
The purpose of the trial, the entailed procedures, and the potential risks and benefits will be 
explained in person.  Those who agree to the study will complete an informed consent 
process with the study coordinator and/or study physician, at which time it will be verbally 
verified that the subject comprehends the purpose of the trial, and the risks and benefits of 
participating.  The subject will be provided adequate time to read the consent and to ask 
questions about the study.  The subject will be offered a signed copy of the informed 
consent and a copy will be filed in the patient’s medical record.  The signed original 
consent form will be stored confidentially according to site IRB requirements.  Patients 
who meet the inclusion criteria will be consented, registered at DCC, assigned a PIN and 
study identification number (refer to section 5.1), and enrolled into the study.  
 
6.3 Active Surveillance & Clinic Assessments 
 
 
Each study participant will be seen a minimum of five times over the 24-month study 
period by a study physician or study team member at the clinic (baseline visit and every six 
months (+/- 2 months) for a two year period).  The maximum number of visits depends on 
if the patient has repeated infections or colonization for MRSA; this will likely not exceed 
12 visits during the 2 year study period.  This includes Visit 1 to sign the informed consent 
and register subject with DCC (assigned a PIN).  Women of childbearing age will undergo 
a urine pregnancy test to assure that she meets inclusion/exclusion criteria. Enrolled 
patients will fill out questionnaires including data on prior MRSA or soft tissue infections, 
recent hospitalizations, demographic information (age, race, sex), substance use (alcohol, 
tobacco and illicit drugs), current and recent (within the past 12 months) antibiotics, 
current receipt of highly active antiretroviral therapy (HAART), contact with persons with 
a history of soft tissue infections and/or MRSA, relative or contact who works in the 
healthcare setting, exercise habits, sexual activities, sexually transmitted diseases, and 
activities previously associated with MRSA including sports, use of public baths/saunas, 
and hygienic practices (refer to case report forms).  Each participant will have swabs of 
their nares, throat, axilla, groin, and perirectal area obtained for determining MRSA or 
MSSA colonization.  Study coordinators will examine the patient’s medical records and 
the hospital computer database for medication use, medical conditions including MRSA or 
soft tissue infections, hospitalizations, sexually transmitted diseases, and HIV data 
including CD4 count, HIV viral loads, and CDC staging.   

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
15 
 
During regular study visits 2, 3, 4, and 5, patients will have repeated swabs, 
questionnaires and review of their medical record which occurs every six months (+/- 2 
months). The study duration for each participant is 24 months.   
 
 
 
Patients will have the following swabs to detect colonization of MRSA or MSSA 
performed:  
• one swab of both nares; 
• one swab of the throat 
• one swab of the bilateral groin areas;  
• one swab of the axilla areas; and 
• one swab of the perirectal area.   
 
 
Patients will be evaluated at 6, 12, 18, and 24 study months (± 2 months) for repeat 
swabs (1. one swab of both nares; 2. one swab of the throat; 3. one swab of the bilateral 
groin areas; 4. one swab of the axilla areas; and 5. one swab of the perirectal area).  
Patients will also complete questionnaires regarding recent antibiotic use, recent soft tissue 
infections, recent sexually transmitted diseases, hospitalizations, substance use, sexual 
activities, and activities previously associated with MRSA (refer to case report forms).  
Study coordinators will search the patient’s medical records and the hospital computer 
database for medication use, medical conditions including MRSA or soft tissue infections, 
hospitalizations, sexually transmitted diseases, and HIV data including CD4 count, viral 
loads, and CDC staging.   
 
Culture results regarding MRSA carriage are to be finalized within 3-4 days of 
collection. Patients found to have a positive culture for MRSA during the study period 
from the colonization swabs will be randomized in a 1:1 double-blinded fashion to 
mupirocin (Bactroban®) nasal ointment twice daily for seven days plus hexachlorophene 
(pHisoHex®) washes with showering once daily for seven days or to a placebo nasal 
ointment (white petroleum) and a placebo body soap with no antimicrobial activity for 
seven days.  The patient will be randomized within 7 days of the receipt of the MRSA 
positive culture result.  Women of childbearing age will have a urine pregnancy test to 
assure they are not pregnant before dispensing of these medications; women found to have 
a positive pregnancy will be terminated from the study.   
 
Patients who are colonized with MRSA and who reside locally to the medical 
treatment facility and are able to return to the clinic will have repeat swabs (five swabs 
from sites listed above) every month (+/- 7 days).  A month will be specifically defined as 
28 days.  Those who have repeat positive colonization swabs during this initial 6 month 
follow-up period will be observed.  This data will access the efficacy of decolonization 
procedures on MRSA carriage rates.  Patients who are not local to the clinic will not have 
these repeat swabs performed, but rather will be seen at the next scheduled 6 month study 
visit.  Adherence to the study medications will be assessed at the next scheduled study visit 
by a patient questionnaire (refer to case report forms).  Each time a patient has a positive 
isolate for MRSA or MSSA, this will be frozen and saved for molecular analysis to 
determine the most common molecular types colonizing HIV patients and to determine if 
patients acquire new strains or remain colonized with the same strain over time.  

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
16 
All study patients (both those initially found to be colonized with MRSA and those 
with negative colonization swabs) will be re-evaluated in six month intervals (+/- 2 
months) until the end of the study.  Patients found to be positive at these subsequent 6 
month intervals, will be randomized again, treated and followed as described above.  
During the last study visit (at the 2-year time period), patients will have swabs, but not 
undergo randomization.  Hence, every 6 months, patients positive during that visit for 
MRSA colonization will be re-randomized in a 1:1 double-blinded fashion to mupirocin 
(Bactroban®) nasal ointment twice daily for seven days plus hexachlorophene 
(pHisoHex®) washes with showering once daily for seven days or to a placebo nasal 
ointment (white petroleum) and a placebo body soap with no antimicrobial activity for 
seven days.  Repeat randomization will occur every 6 months for those carrying MRSA. 
For example, some patients initially randomized to receive Bactroban® and pHisoHex®, 
may later be randomized to the placebo arm, and vice versa. 
 
 
 
Obtain Swabs from 5 locations for MRSA Colonization 
 
 
 
Positive  
 
 
             Negative 
 
 
 
 
 
 
 
Randomize to Bactroban® nasal ointment and PHisoHex® soaps x 7 days               
  or to the placebo nasal ointment and placebo body soap x 7 days 
 
 
 
 
                    
 
      Local Patients: 
          Repeat swabs at five sites each month (+/- 7 days) x 6 mos; 
          no specific therapy administered at these time points, however  
          cultures are obtained to analyze for clearance of colonization 
      Non-local patients: 
          Follow-up at 6 month time period 
 
 
 
 
 
 
 
 
 
                                                       
 
                                   Repeat swabs in 6 months (+/- 2 months) for 2 year time period 
                                         
                             
Begin at the top of diagram again every 6 months (+/-2 months).  If patient is found to be positive on swabs, 
they are re-randomized to one of the two treatment groups for every 6-month positive swab. 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
17 
 
Patients will be asked to report to their enrolling HIV clinic for any soft tissue 
infections or any infection thought to be secondary to MRSA; if able, cultures of the 
wound site will be obtained.  Blood cultures will be obtained at the primary provider’s 
discretion depending on the presence of fevers, toxemia, and the extent of soft tissue 
involvement.  Patients will also have repeated screening for colonization including nares, 
throat, groin, axilla, and perirectal swabs (5 total swabs) at this time.  CD4 counts and an 
HIV viral load will be obtained at the time of the soft tissue infection or with any MRSA 
infection for patients presenting to the enrolling site.  Patients with positive wound culture 
and/or blood cultures for MRSA will be classified as a “MRSA infection.”  Those with a 
soft tissue infection without positive cultures from these sites will be classified as a “Soft 
Tissue Infection NOS.”  The patient will be treated with intravenous or oral antibiotics 
and/or surgical procedures at the discretion of the medical provider that the patient presents 
to for evaluation.  Patients who have an infection while located remotely from the HIV 
clinic will be given a contact information card and will be asked to call the site PI or study 
coordinator at their enrolling site to notify them of the infection.  The site PI or study 
coordinator will try to arrange for the aforementioned tests to be performed at the local 
medical clinic; CD4 counts and HIV viral loads will not be performed for patients 
presenting remotely to the enrolling site.  In addition, coordinators will gather information 
on the tests and treatments performed.  Patient questionnaires will be completed for 
patients experiencing a soft tissue infection or MRSA infection (refer to case report forms). 
 
Patients experiencing an infection will be offered decolonization medications based 
on their most recent randomization assignment; those previously randomized will be 
maintained in their group, while those experiencing a soft tissue infection and having a 
positive colonization culture for the first time will be randomized to either mupirocin 
(Bactroban®) nasal ointment twice daily for seven days and hexachlorophene (pHisoHex®) 
washes with showering once daily for seven days or to a placebo nasal ointment (white 
petroleum) and a placebo soap with no antimicrobial activity for seven days.  Patients with 
a positive soft tissue culture but no positive swabs from the nares, throat, groin, axilla, or 
perirectal areas, will not be randomized.  If the primary clinician caring for a patient who 
experienced a MRSA infection desires to decolonize a patient regardless of the patient’s 
randomization group, this is permitted, but must be documented and these participants will 
be removed from the “placebo group” for the analysis.  
 
All cultures (from colonization sampling, wound and blood cultures) which are 
positive for MRSA or MSSA at the local medical treatment facilities laboratories will be 
preserved by freezing the isolates at-70 degrees C; these samples will be batched (isolates 
will be held at the primary facility and sent on a periodic basis) and sent overnight with dry 
ice to the NMCSD.  This site will collect the specimens and send them to the laboratory at 
SAMMC which will perform testing on the isolates for confirmation of MRSA, antibiotic 
susceptibility testing (including mupirocin), and molecular analysis (to include multilocus 
sequence testing, PVL PCR, and other virulence factors).  Some local laboratories (e.g. 
NMCSD) are also performing susceptibility testing on the isolates; this information will be 
collected if available.  SAMMC will also repeat all susceptibility testing on all isolates at 
their facility.  All samples sent to the laboratory at SAMMC will be labeled only with a 
PIN number of the patient.  The staff at the SAMMC laboratory will not have access to 
personal identifiers and will have no way of linking their results to a patient name.  Results 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
18 
will be reported to the study lead PI using this unique identifier, together with a SAMMC-
assigned identifier.  These data will be utilized to characterize the MRSA isolates 
colonizing and infecting HIV patients, understanding the relationship between colonizing 
and infection-related isolates, and to determine if HIV patients acquire new strains or 
remain colonized with the same strain over time. 
 
The primary endpoint of the study is the effectiveness of decolonization procedures 
with application hexachlorophene (pHisoHex®) soaps and nasal mupirocin (Bactroban®) 
compared to placebo among patients found to be colonized with MRSA in the prevention 
of future colonization with MRSA.  As a secondary part of the study’s objectives, we will 
also examine the effectives of these decolonization procedures on infections with MRSA 
and on soft tissue infections. 
   
The following assessments will be performed: 
 
a.    Clinical (Visits 1, 2, 3, 4, 5, unscheduled visits)  
 
1. Informed Consent (visit 1 only) 
2. Patient Questionnaires regarding medical history, medication use, and 
potential risk factors for MRSA 
3. Demographics (visit 1 only)  
 
4. Review of patients medical record by study coordinators 
5. Study medication dispensing (unscheduled visits for positive MRSA 
colonization only) 
6. Adverse event review (unscheduled visits in which patient receives a 
study medication only) 
7. Medication adherence questionnaire (visit following decolonization 
therapy) 
 
b.    Laboratory Values (Visits 1, 2, 3, 4, 5, unscheduled  
         visits) 
                 1. Swabs for MRSA colonization of the nares, throat, groin, axilla, 
                             and perirectal areas (5 swabs) 
                        2. Pregnancy test (visit 1; visits for MRSA colonization before 
 
decolonization medications are prescribed for women of  
 
childbearing age) 
                        3. CD4 count and HIV viral load (MRSA or soft tissue infection visit  
                            only) 
                        4. Blood cultures (two sets) at the physician’s discretion  
                            (MRSA or soft tissue infection visit only) 
                       5.  Wound culture (MRSA or soft tissue infection visit only) 
 
 
6.4 Details of Laboratory Studies 
 
Testing 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
19 
Swabs for MRSA:  
 
Patients will have their nares, throat, groin, axilla, 
and perirectal areas swabbed for MRSA colonization 
and these swabs will be sent to the microbiology 
laboratory at the clinical site for determination of the 
presence of MRSA or MSSA at each of these sites. 
 
 
  
 
The laboratory will provide culture results within 3-4 
days of swab collection.  
Wound and blood cultures:  Patients with an active skin or soft tissue infection 
will have a culture of the wound performed and sent 
to the microbiology laboratory of the clinical site for 
determination of the presence of MRSA or MSSA at 
each of these sites.  Blood cultures may be ordered 
based on the discretion of the primary physician. 
HIV studies:    
 
CD4 count by flow cytometry and HIV viral load will 
be performed at each clinical site’s lab. 
Pregnancy test:  
 
Women of childbearing age will have a pregnancy 
test at baseline to assure she meets 
inclusion/exclusion criteria.  This test will be 
repeated if she is found to be colonized with MRSA 
before dispensing the decolonization medications; if 
she is found to have a positive pregnancy test, her 
study participation will be terminated. 
 
 
6.5 Clinical Outcomes 
 
Clinical outcomes as defined by the eradication of MRSA carriage, as well as the incidence 
of MRSA and soft tissue infections, will be examined and the effect of decolonization 
procedures for patients carrying MRSA in their nares, throat, groin, axilla, and perirectal 
areas will be assessed.  
 
6.6 Laboratory Outcomes 
 
The primary and secondary study outcomes involve laboratory data.  The measure of the 
effect of decolonization procedures will include the presence of MRSA on repeated swabs 
to assess the efficacy of these medications on clearing MRSA colonization.  In addition the 
effect of MRSA infections on the CD4 count and HIV viral load will be assessed.  
 
6.7 Randomization Procedures 
 
Patients who are found to be colonized with MRSA will be randomized to receive either 
mupirocin (Bactroban®) nasal ointment plus hexachorophene (pHisoHex®) body washes 
for seven days or a placebo nasal ointment (white petroleum) and a placebo body soap with 
no antimicrobial activity for seven days.  The patient will be randomized within 7 days of 
receiving the MRSA positive culture result.  Women of childbearing ages will undergo a 
pregnancy test and those found positive will be terminated from the study.  A 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
20 
randomization list will be generated by a computer program at one controlled location and 
administered by the Infectious Disease Clinical Research Program (IDCRP), Data 
Coordination Center (DCC).  Assignments will be made at the time that a patient has a 
positive swab for MRSA colonization.  Patients with repeat positive colonization cultures 
at the 6-month intervals will be re-randomized at these time periods.  Enrollment will be 
stratified by site to ensure an equal number of participants in each study arm per site.   
 
6.8 Study Drug 
 
Mupirocin (Bactroban®) 2% nasal ointment and hexachlorophene (pHisoHex®) 3% soap 
will be obtained through the pharmacy at the NMCSD.  In addition, we will obtain white 
petroleum as a placebo nasal ointment and a body soap without antibacterial activity as a 
placebo.  Upon receipt of these medications, the pharmacist at the NMCSD will initiate a 
drug accountability log entitled Investigational Agent Accountability Record.  This record 
will be maintained as a perpetual inventory of both mupirocin (Bactroban®) and 
hexachlorophene (pHisoHex®). 
 
Once obtained from the NMCSD pharmacy, mupirocin (Bactroban®) nasal ointment, 
hexachlorophene (pHisoHex®) soap, and the placebo ointment and soap will be provided 
to each site following a written request via the Clinical Drug Request Form, written 
confirmation of protocol approval from the IRB of the site requesting the drug, and a copy 
of the current Randomization Assignment List (if requesting additional drug).  The Clinical 
Drug Request Form and Randomization Assignment List (if applicable) will be faxed to 
the NMCSD pharmacist each time the drug is requested.  Once the above documentation is 
obtained, the NMCSD pharmacist will send the requested amount of these medications to 
the pharmacist at the requesting site.  The shipment will contain an Investigational Drug 
Shipment Form (Shipping Manifest Form), which must be faxed to the NMCSD 
pharmacist following receipt of each medication shipment.  In addition, the drug shipment 
will contain a Study Agent Accountability Log and a Randomization Assignment List.  As 
each site differs in policy with regard to handling investigational medications, the Site 
Principal Investigator and pharmacist at each site will be accountable for maintaining the 
Study Agent Accountability Log and the Randomization Assignment List as well as 
following site-specific procedures of drug accountability, storage and dispensing. 
 
6.9 Adverse Event Reporting  
 
An adverse event will be defined as follows: “Any untoward medical occurrence in a 
patient or clinical investigation subject administered a pharmaceutical product and which 
does not necessarily have a causal relationship with this treatment.  An adverse event (AE) 
can, therefore, be any unfavorable and unintended sign, symptom, or disease temporally 
associated with the use of a medicinal (investigational) product, whether or not related to 
the medicinal (investigational) product” (ICH 1.2).  As the antibacterial topical agents are 
given for a 7-day course, AEs will only be recorded temporarily near the time of 
medication administration (within 10 days of the last dose utilized).  Adverse events will 
be identified by patient interviews during medical follow-up visits by a study investigator. 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
21 
Since the study only utilizes topical antibacterial agents, abnormal laboratory values will 
not be recorded as AE’s.  
 
6.9.1 Grading Adverse Events for Severity 
All AEs will be graded for severity. Selected AEs will be graded in severity as defined in 
Attachment A.  Adverse events will be graded as mild, moderate, severe, life-threatening, 
or fatal.  Mild adverse events (grade 1) are often transient, do not interfere with subject’s 
usual function and no intervention may be required.  Moderate adverse events (grade 2) 
interfere to some extent with usual function; there may be some impairment of functioning 
without resulting in loss of work or cancellation of social activities.  Grade 2 adverse 
events are uncomfortable or an embarrassment.  Severe adverse events (grade 3) 
significantly interfere with usual function, may require bed rest and/or result in loss of 
work or cancellation of social activities.  Grade 3 adverse events produce significant 
impairment of functioning or incapacitation, and medical intervention is often required.  
Life-threatening (grade 4): adverse events result in extreme limitation in activity, 
significant assistance is required and immediate medical intervention or therapy is required 
to prevent death. 
 
6.9.2 Relatedness of Adverse Events to the Study Drugs 
Any AE that occurs in a patient/study subject receiving study medications will be assessed 
for relationship to the drug/investigational product.  A causal relationship means that the 
drug/ investigational product caused or is reasonably likely to have caused the AE.  This 
usually implies a relationship in time between the drug/ investigational product and the 
AEfor example, the AE occurred shortly after the patient/study subject received the 
drug/investigational product.  
 
The best estimate at the time of reporting of the causal relationship between the 
experimental intervention and an adverse event and the degree of certainty about causality 
will be graded as follows: 
 
Definitely Related: The adverse event and administration of study agent are related in time, 
and a direct association can be demonstrated (e.g., disappears or decreases with reduction 
in dose or cessation of drug/investigational product and recurs with re-exposure). 
 
Probably Related: The adverse event and administration of study agent are reasonably 
related in time and/or follows a known pattern of response, and the adverse event is more 
likely explained by study agent than other causes. 
 
Possibly Related: The adverse event and administration of study agent are reasonably 
related in time and/or follows a known pattern of response, and the adverse event can be 
explained equally well by causes other than study agent (e.g., could readily have been 
produced by the subject’s clinical state or could have been due to environmental or other 
interventions). 
 
Unlikely Related: A potential relationship between study agent and the adverse event could 
exist (i.e., the possibility cannot be excluded), but the adverse event is most likely 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
22 
explained by causes other than the study agent (e.g., could readily have been produced by 
the subject’s clinical state or could have been due to environmental or other interventions) 
                            
Not Related:  The adverse event is clearly due to extraneous causes (e.g., underlying 
disease, environment) or exposure to the investigational product has not occurred.  Such 
events MUST have an alternative, definitive etiology documented in the patient’s medical 
record.  
 
Serious adverse events (SAEs) are adverse events, whether related to the study agent or 
not, that result in: 1) death, 2) threat to life, 3) inpatient hospitalization or prolongation of 
existing hospitalization, 4) persistent or significant disability or incapacity, 5) congenital 
anomaly or birth defect, 6) overdose, or 7) any medical event which requires treatment to 
prevent one of the medical outcomes previously listed. 
 
SAEs and subject discontinuations will be reported to the Medical Monitor.  Each subject 
will be carefully observed for signs of intolerance or toxicity.  If any adverse reaction is 
noted, the subject will be treated as medically indicated.  The subject may be withdrawn 
from the study if it is felt by the clinical investigators that the subject is at an undue risk 
from further participation.   
 
The Site Principal Investigator will report any serious or unexpected adverse reactions 
immediately to the Medical Monitor.  Within 24-48 hours the Site Principal Investigator 
will also use telephone or fax transmission to notify the IRB at their site (timeframe 
depends on local IRB requirements) and Lead Principal Investigators at which time the 
Lead Principal Investigator and the site Medical Monitor will determine if the study should 
continue.  The Medical Monitors and the Principal Investigator (PI) will be responsible for 
reviewing the cumulative safety data.  
 
Any event, whether expected or unexpected, that is classified as a SAE which is fatal or 
non-fatal will be reported within 48 hours to the USU IRB once the PI is made aware of 
the event.  Non-serious adverse events related to the receipt of the study medication will be 
reported at time of the continuing review. 
 
Submission of serious and unexpected adverse experiences is the responsibility of the 
Principal Investigator. 
 
 6.10 Termination 
 
A subject’s participation will be terminated if one of the following occurs: 
 
a. 
Subject voluntarily withdraws 
b. 
Subject fails to comply with study procedures  
c. 
Decision in the best interest of the patient 
d. 
Patient is no longer eligible for care at the military HIV clinics 
e. 
 Patient becomes pregnant or decides to become pregnant during the two-
 
year study period 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
23 
f.      The patient begins employment as a healthcare worker with direct patient 
 
contact 
 
A subject who develops a rash or significant adverse event due to study medication will be 
discontinued from treatment but will be encouraged to continue to undergo follow up 
including study visits for completing questionnaires and swabs for MRSA colonization 
every 6 months (+/- 2 months) until study completion; the patient will not be randomized 
to one of the treatment arms if he/she is found to be positive again for MRSA colonization.  
The subject may be withdrawn from the study if it is felt by the clinical investigators that 
the subject is at an undue risk from further participation.   
 
The subject will require a termination visit if withdrawn from the study.  If a subject’s 
participation in this study is terminated, they will be offered medical standard of care and a 
medical evaluation, to include clinical laboratory studies as needed.  The investigator will 
complete the Completion/Discontinuation CRF. 
 
 
VII. STATISTICAL ANALYSES 
 
 
There are four primary questions to be answered to address this study’s primary 
objective. These, and an analysis designed to answer the question, follow.  
(1) What is the hexachlorophene/mupirocin treatment effect to clear MRSA 
colonization compared to placebo?  We will also examine if these decolonization 
procedures are effective at reducing MRSA infections and skin/soft tissue 
infections compared to placebo.  We propose to pool the data at 6, 12, 18, and 24 
months as if they were independent and conduct a chi-square or Fisher’s exact test 
of contingency.  These analyses will be conducted for colonization and infection 
separately.  The proposed pooling of this study design assumes that there is no 
persistent or repeated-treatment effect and that there is no patient-to-patient 
difference in susceptibility.  These effects will be investigated in the following 
questions. 
(2) Is the treatment effect different for repeat administrations of 
hexachlorophene/mupirocin?  The rate of MRSA positive versus negative for 
recolonization reoccurrence through the sequence 1 versus 2 versus 3 versus 4 
treatments will be assessed by a test of trend. 
(3) Is there a persistent or repeated-treatment effect?  The overall rates of MRSA 
recolonization at 6, 12, 18, and 24 months will be assessed by a test of trend. 
(4) Is there an individual propensity for susceptibility and what are the treatment 
differences between placebo and hexachlorophene/mupirocin in terms of length of 
time for being negative for MRSA colonization on repeated testing?  A Kaplan-
Meier long-rank test will be conducted on three groups: initially negative, initially 
positive treated with hexachlorophene/mupirocin, and initially positive treated with 
placebo, where survival is defined as not having acquired MRSA. 
 
 
For the secondary objectives, part (a) will be assessments of the rates in which  
prevalence is defined as the number of patients colonized with MRSA at the beginning of 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
24 
the study divided by the total population studied, and the incidence as the number of new 
infections per calendar time divided by the total population studied.  For objective (b) 
examining for predictors of MRSA, we will create a multivariate logistic regression model 
and use a backward stepwise approach.  For part (c), to evaluate if there is a significant 
change in the CD4 count and/or viral load pre- versus during a MRSA infection we will 
utilize a 1-way ANOVA.  We will also compare pre-MRSA infection with after MRSA 
resolution as well as the counts during the infection with those after resolution.  Finally, 
objective (d) will be a descriptive analysis of the molecular and microbiologic 
characteristics of the isolates.  The main statistical data from the retrospective chart review 
study of HIV patients at NMCSD will be presented by descriptive analyses.  We will 
compare demographics and HIV clinical data between those with and without MRSA 
using rank sum tests and Fisher’s exact tests depending on the variable characteristics 
(categorical or continuous).  A multivariate logistic regression model for predictors of 
MRSA will then be developed using a backward stepwise approach using Stata software. 
The sample size calculation for this study is based on the primary objective of the 
study which is to evaluate the effectiveness of decolonization procedures with application 
of nasal mupirocin (Bactroban®) and hexachlorophene (pHisoHex®) soaps compared to 
placebos with no antibacterial activity among patients found to be colonized with MRSA 
in the prevention of future colonization with MRSA.  We will also examine the number of  
infections with MRSA and soft tissue infections as secondary measures of the primary 
objective. 
The rate of MRSA colonization of the nares was 1% in a recent study involving the 
general US population [41].  Among HIV-infected patients this rate is higher, with one 
study showing a carriage rate of 27.6% [11].  However, other studies had rates of 3-9% 
among their HIV-infected patients [26, 27, 42].  The MRSA infection rate among HIV-
infected persons is approximately 13 cases/1000 person-years in one study that examined 
3,455 patients over three years with 94 MRSA infections [7]; our rate at NMCSD appears 
higher with 40 cases/1000 persons in the year 2005 [12].   
 
In a study examining both MSSA and MRSA colonization rates, after treatment 
with mupirocin (Bactroban®), colonization was eradicated in 93%, whereas 85% who 
received placebo remained colonized (P<.001). At day 90 after study entry, 61% of the 
residents in the mupirocin group remained decolonized [36].  In a study by Ellis et al 
involving 812 soldiers over a 8-10 week period of training, of those with MRSA 
colonization without treatment for decolonization, 38% developed a soft tissue infection 
[43].  
Using these data, assuming 10% of the HIV patients would be colonized, that half 
would be randomized to each treatment group, and that 85% in the non-treatment arm 
would remain colonized versus 7-39% (mean 23%) of the treated would remain colonized, 
we calculated the following sample sizes: 
 
 
 
 
 
Colonization 
rate of the 
Power 
Alpha level 
Sample size 
per group 
Total sample size 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
25 
Treated Group 
0.07 
.80 
.05 
80 
160 
0.23 
.80 
.05 
120 
240 
0.39 
.80 
.05 
210 
420 
 
Hence to show a statistically significant decline in colonization rates using mupirocin 
(Bactroban®) and hexachlorophene (pHisoHex®), up to 420 patients would be required.  
Given potential lost to follow-up events and that the colonization rate or clearance rates 
may vary, we propose to enroll 550 participants, such that 500 participants are followed 
throughout the study period.  Given this sample size and the estimate of a 10% 
colonization rate over the study period, we would estimate that 50-55 participants will be 
randomized.  Since participants with repeat colonization events may differ from those with 
first time MRSA colonization and may differ in response to decolonization medications, 
we will also examine as a secondary analysis of the primary endpoint only those with 
unique randomizations. 
 
 
For showing a significant difference in the number of infections between the two treatment 
groups, assuming 38% of the no specific treatment group and 10% of the treatment group 
will develop infection, a sample size of 860 would be needed; of note, this is a secondary 
objective and not the primary basis of the sample size calculation for this study.  For 
smaller changes in the difference in the rates between groups, larger sample size would be 
needed.  Of note, the first rates (38% vs. 10%) were determined during an 8-10 week 
period and our study involves 6-month periods over a total two year period; on the other 
hand, this military training population studied for these estimates may have a higher rate 
than our HIV patients.   
 
Infection 
Rate in 
Treated 
Group 
Infection 
Rate in 
Placebo 
Group 
Difference 
in Infection 
Rate 
Between 
Groups 
Power 
Alpha 
level 
Total 
sample size 
for one time 
period 
Total 
sample size 
for every 6 
month 
evaluations 
10% 
38% 
28% 
.80 
.05 
860 
277 
10% 
30% 
20% 
.80 
.05 
1440 
464 
10% 
25% 
15% 
.80 
.05 
2260 
729 
5% 
15% 
10% 
.80 
.05 
3200 
1032 
 
To account for the study design of patients being re-examined every 6 months over a two-
year period (a total of five visits) and re-randomized at each of these intervals with new 
infections being counted as separate events, the sample size required was notably smaller 
(last column in table).  The calculations accounted for a progressive decrease in 
colonization and infection rates over the course of the study since patients would be given 
decolonization medications depending on their randomization assignment. 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
26 
Using these data, we proposed a sample size of 500 participants to find statistically 
significant results; given the long duration of follow-up and the possibility for attrition, we 
will enroll 550 participants accounting for 50 drop-outs.  
 
Overall, we plan to enroll 550 participants into the study with the goal of a minimum of 50 
randomizations for scientific significance.  In addition, we will also examine unique 
randomizations, defined as a subject’s initial randomization (not counting re-
randomizations), as a sub-analysis of the primary endpoint.  Of note since the primary 
endpoint includes completion of the 6 month follow-up visit after initial randomization, at 
least 50 subjects with these data are needed.   
 
We plan to conduct an interim examination yearly (after at least one-half of subjects are 
enrolled) to determine the adequacy of the design assumptions and sample size, given that 
there is little literature regarding the expected colonization and infection rate in this 
specific (HIV) population.  Also, approximately every year we will conduct an 
examination of the epidemiologic data regarding the prevalence and incidence of MRSA in 
this cohort, as well as a safety assessment. 
 
We also calculated a sample size for the secondary objective which was to determine the 
predictors of MRSA colonization and infection among HIV-infected persons including 
examination of demographics, sexual activity, hygienic procedures, drug use, antibiotic 
and HAART medications, sexually transmitted diseases and HIV control.  Of note, the 
other secondary objectives do not lend themselves to sample size calculation due to the 
paucity of baseline data in the literature.  Predictors for MRSA were examined in three 
studies including Mathews et al, Lee et al, and our retrospective work [7, 12, 13].  For a 
power at 80%, alpha of 0.05, and examining 20 potential predictors with an R2 of 0.10, we 
would need to enroll 205 patients in the study (sample power analysis, SPSS).  As we 
examined more predictors, a larger sample size (500 to 550) is preferred. 
 
VIII.  DATA ENTRY AND ANALYSES 
 
The IDCRP Data Coordination Center (DCC) will enter completed CRF data and manage 
all study data.  In order to comply with requirements of maintaining subject confidentiality, 
only the subject’s participant identification number (PIN) will be used to identify the 
research information (as detailed below in section IX).  A computer program generates the 
PIN number randomly.  The DCC Data Management Specialist will be the only one 
authorized to have access to view full identifying information within the database.  The 
individuals with access to the data will be study coordinators designated by the PI of the 
project and the site PI according to the agreed upon data management plan. Regulatory 
staff from the Regulatory Compliance and Human Subjects Protection Branch 
(RCHSPB)/SAIC-Frederick, Inc. will also have access to view full identifying information 
during monitoring visits and auditing.  After data entry, data will be analyzed using SPSS 
13.0 and SAS 8.0 for the purpose of publication of significant study findings; these 
publications will not disclose personal information such as patient names.  The data and 
CRFs will be maintained as per local IRB requirements. 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
27 
IX.  STORING AND DISSEMINATION OF DATA 
 
Upon enrollment, each subject will be assigned a unique participant identification number 
(PIN), which will include no patient identifiers.  A patient will be assigned a PIN centrally 
once the patient agrees to participate in a IDCRP study. If a patient agrees to participate in 
other IDCRP studies, this same PIN will be used to link that patient to these other studies. 
For instance, if a patient is already enrolled into the Natural History Study, the same PIN 
will be used for all future IDCRP studies.  This PIN and the data collected will be 
maintained in a secure password protected database at DCC.  The master link between the 
new PIN for this study and the patient’s identifying information will be kept by the Study 
Coordinators at each site in a locked, secure location.  The master link will be maintained 
at DCC after the study’s conclusion.  In addition, each participant will be assigned a 
unique study identification number designating the clinical site of enrollment and a number 
assigned to that specific individual.  
  
During the study, CRFs from each patient will be stored in a locked file cabinet in the 
office at each clinical site.  In order to comply with requirements of maintaining subject 
confidentiality, only the subject’s study number will be used to identify the research 
information.   
 
It is expected that these data will be reported in both scientific journals and scientific 
meetings.  Confidentiality of subjects will be maintained in all forms of reporting.  
Volunteers will be informed in general terms of the results as soon as practical. 
 
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonization (ICH) Guideline for Good Clinical Practices (GCP) and any applicable 
regulatory requirement(s).  Monitors under contract to the NIAID will visit the clinical 
research site to monitor all aspects of the study in accordance with the appropriate 
regulations.  
 
The objectives of a monitoring visit are as follows:  
• To verify the prompt reporting of all data points, including reporting SAEs, 
checking availability of signed informed consent;  
• To compare individual subjects records, Case Report Forms (CRFs) and the source 
documents (supporting data, laboratory specimen records and medical records to 
include physician progress notes, nurse' notes, subjects' hospital charts); and 
• To ensure protection of study subjects, compliance with the protocol, and accuracy 
and completeness of records.  
 
The monitors will also inspect the clinical site regulatory files to ensure that regulatory 
requirements (OHRP/ICH-GCP) are being followed.  During the monitoring visits, the 
investigator (and/or designee) and other study personnel will be available to discuss the 
study progress and monitoring visit. 
 
The investigator (and/or designee) will make study documents (e.g., consent forms, CRFs) 
and pertinent hospital or clinical records readily available for inspection by the local IRB, 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
28 
the site monitors, and the NIAID staff for confirmation of the study data. 
 
 
X.  FACILITIES TO BE USED 
 
10.1 Laboratory 
 
Each of the clinical sites will utilize their own laboratory for the testing of the presence of 
MRSA and MSSA in swabs or cultures, urine pregnancy tests, and for CD4 counts and 
HIV viral loads among those patients with a MRSA infection.  MRSA and MSSA isolates 
will be frozen at -70 degrees C at the clinical sites, batched, and sent overnight on dry ice 
to the NMCSD; these specimens will be shipped to the laboratory at SAMMC in Texas for 
MRSA confirmation, antibiotic susceptibility testing and molecular analysis for the SCC 
type and virulence factors such as the PVL genes.      
 
 
1. Naval Medical Center San Diego  
 
San Diego, CA 92134-5000 
 
2. Walter Reed National Military Medical Center 
 
 
Bethesda, MD 20889 
 
3. Wilford Hall Ambulatory Surgical Center 
 
 
 Lackland AFB, TX 78236 
 
4. San Antonio Military Medical Center 
 
Fort Sam Houston, TX 78234 
 
5.  Naval Medical Center Portsmouth 
                 Portsmouth, Virginia 23708 
 
 
10.2 Clinical 
 
Each clinical site will care for the patients. 
 
1. Naval Medical Center San Diego 
 
San Diego, CA 92134-5000 
 
 
2.  Walter Reed National Military Medical Center 
 
 
Bethesda, MD 20889 
 
3.  Wilford Hall Ambulatory Surgical Center 
 
 
Lackland AFB, TX 78236 
 
4. San Antonio Military Medical Center 
 
 
Fort Sam Houston, TX 78234 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
29 
 
5.  Naval Medical Center Portsmouth 
                 Portsmouth, Virginia 23708 
 
 
10.3 Planning and Use for Storage of Biological Specimens 
 
 
All blood drawn for HIV viral loads, CD4 counts, complete blood counts, or blood 
cultures will be destroyed after the test is performed at the local laboratory site with no 
storage of any blood samples.  This is the local standard of the individual laboratories 
participating in this study. 
 
Isolates identified to be MRSA or MSSA at the individual participating sites will be 
stored at -70oC in the local microbiology laboratory.  Periodically, these specimens will be 
mailed frozen via Federal Express using proper labeling for biological specimens to the 
Naval Medical Center San Diego.  Specimens will be shipped to the laboratory at SAMMC 
in Texas for molecular characterization.  These specimens do not contain any of the 
patients’ cells or genetic material, but rather our bacteria isolated from clinical specimens. 
 
XI. TIME REQUIRED TO COMPLETE 
 
Enrollment will take approximately 30 months.  Another 24 months will be required to 
complete all of the study visits and 6 months for data analyses.  Total study time is 
approximately 60 months. 
 
XII. NUMBER OF SUBJECTS TO BE STUDIED 
 
The study population will consist of a total of 550 volunteers.  
 
XIII. NUMBER OF CHARTS TO BE REVIEWED 
 
Medical charts will be reviewed on an ongoing basis by five collaborative research sites 
until 550 participants have been enrolled.  Charts from all HIV-infected patients in the HIV 
clinic at NMCSD will be reviewed for the retrospective cohort. 
 
XIV.  FUNDING IMPLICATIONS 
 
Required resources from NIH/NIAID will be provided by the Henry M. Jackson 
Foundation (HJF), through a cooperative agreement between the HJF and the NIH/NIAID.  
There will be no funding from outside resources.  See attached budget. 
 
XV.   DATE PREPARED 
 
May 20, 2006 
Revised September 20, 2006; Version 1.0 
Revised April 23, 2007; Version 1.1 
Revised November 21, 2008; Version 1.2 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
30 
Revised February 26, 2009; Version 1.3 
Revised May 29, 2009; Version 1.4 
Revised November 15, 2010; Version 2.0 
Revised February 10, 2011; Version 3.0 
Revised July 20, 2011; Version 4.0 
Revised September 1, 2011; Version 5.0 
Revised May 25, 2012; Version 6.0 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
31 
XVI. BIBLIOGRAPHY  
 
1. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus 
aureus disease in three communities. N Engl J Med. 2005;352:1436-1444. 
2. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant 
Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol. 
2003;24:451-455. 
3. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by 
community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl 
J Med. 2005;352:1445-1453. 
4. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS. Severe Staphylococcus aureus 
infections caused by clonally related community-acquired methicillin-susceptible and 
methicillin-resistant isolates. Clin Infect Dis. 2003;37:1050-1058. 
5. Crum NF. The emergence of severe, community-acquired methicillin-resistant 
Staphylococcus aureus infections. Scand J Infect Dis. 2005;37:651-656. 
6. Fowler A, Mackay A. Community-acquired methicillin-resistant Staphylococcus aureus 
pyomyositis in an intravenous drug user. J Med Microbiol. 2006;55:123-125. 
7. Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically 
significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-
infected adults. J Acquir Immune Defic Syndr. 2005;40:155-160. 
8. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with 
methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban 
hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis. 
2005;41:159-166.  
9. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant 
Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin Infect Dis. 
2003;36:131-139. 
 
10. Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-acquired 
methicillin-resistant Staphylococcus aureus (MRSA) infections in military trainees: review 
of an outbreak in San Diego, California, 2002. J Clin Microbiol. 2004;42:4050-4053. 
11. Pan ES, Diep BA, Charlebois ED, et al. Population dynamics of nasal strains of 
methicillin-resistant Staphylococcus aureus – and their relation to community-associated 
disease activity. J Infect Dis 2005; 192:811-8. 
12. Crum-Cianflone N, Hale B, Burgi A, Utz G, Truett A, Chun H, Bavaro M, TriService 
AIDS Clinical Consortium. Increasing rates of community-acquired MRSA infections 
among HIV-infected persons. Oral Presentation at the XVI International AIDS Conference, 
Toronto, Canada, August 13-18, 2006. 
13. Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated 
methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who 
have sex with men. Clin Infect Dis. 2005;40:1529-1534 
14. Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus 
aureus in correctional facilities – Georgia, California, and Texas, 2001-2003. MMWR 
Morb Mortal Wkly Rep. 2003;52:992-995. 
15. Centers for Disease Control and Prevention. Outbreaks of community-acquired 
methicillin-resistant Staphylococcus aureus skin infections – Los Angeles County, 
California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2003;52:88. 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
32 
16. Zinderman CE, Conner B, Malakooti MA, et al. Community-acquired methicillin-
resistant Staphylococcus aureus among military recruits. Emerg Infect Dis. 2004;10:941-
944. 
17. Nguyen DM, Mascola L, Bancroft E. Recurring infections in a football team. Emerg 
Infect Dis. 2005;11:526-532. 
18. Kazakova SV, Hageman JC, Matava M, et al. A clone of methicillin-resistant 
Staphylococcus aureus among professional football players. N Engl J Med. 2005;352:468-
475. 
19. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in 
healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-
Valentine leukocidin genes. Clin Infect Dis. 2005;40:100-107. 
20. Baggett HC, Hennessy TW, Rudolph K, et al. Community-acquired by methicillin-
resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-
Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis. 
2004;189:1565-1573. 
21. Yamasaki O, Kaneko J, Morizane S, et al. The association between Staphylococcus 
aureus strains carrying Panton-Valentine leukocidin genes and the development of deep-
seated follicular infection. Clin Infect Dis. 2005;40:381-385. 
22. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired 
methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of 
skin and soft-tissue infections. Ann Intern Med. 2006;144:309-17. 
23. Voyich J, Braughton KR, Sturdevent DE, et al. Insights into mechanisms used by 
Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol. 
2005;175:3907-3919. 
24. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant 
Staphylococcus aureus clones in the community. J Clin Microbiol. 2002;40:4289-4294. 
25. Tumbarello M, de Gaetano Donati K, Tacconelli E, et al. Risk factors and predictors of 
mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-
infected patients. J Antimicrob Chemother. 2002;50:375-382. 
26. Villacian JS, Barkham T, Earnest A, Paton NI. Prevalence of and risk factors for nasal 
colonization with Staphylococcus aureus among human immunodeficiency virus-positive 
outpatients in Singapore. Infect Control Hosp Epidemiol 2004;25:438-40. 
27. McDonald LC, Lauderdale TL, Lo HJ, Tsai JJ, Hung CC. Colonization of HIV-
infected outpatients in Taiwan with methicillin-resistant and methicillin-sensitive 
Staphylococcus aureus. In J STD AIDS 2003; 14:473-7. 
28. Braun L, Craft D, Williams R, Tuamokumo F, Ottolini M. Increasing clindamycin 
resistance among methicillin-resistant Staphylococcus aureus in 57 northeast United States 
military treatment facilities. Pediatr Infect Dis J. 2005;24:622-626. 
29. Lewis JS II, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should 
clinicians and microbiologists be concerned? Clin Infect Dis. 2005;40:280-285. 
30a. Manian FA, Senkel D, Zack J, Meyer L. Routine screening for methicillin-resistant 
Staphylococcus aureus among patients newly admitted to an acute rehabilitation unit. 
Infect Control Hosp Epidemiol  2002; 23:51609. 
30b. Rieg G, Daar E, Witt M, et al. Community-acquired methicillin-resistant 
Staphylococcus aureus colonization among HIV-infected men who have sex with men: a 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
33 
point prevalence survey. Presented at the 12th Conference on Retroviruses and 
Opportunistic Infections, February 22-25, 2005; Boston. Abstract 877. 
31. Rashid A, Solomon LK, Lewis HG, Khan K. Outbreak of epidemic methicillin-
resistant Staphylococcus aureus in a regional burns unit: management and implications. 
Burns 2006; 32:452-7. 
32. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative 
Staphylococcus aureus infections. N Engl J Med 2002; 346:1871-7. 
33. Sandri AM, Dalarosa MG, Ruschel de Alcantara L, et al. Reduction in incidence of 
nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive 
care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal 
carriers of MRSA. Infect Control Hosp Epidemiol 2006; 27:185-7. 
34. Kampf G, Kramer A. Eradication of methicillin-resistant Staphylococcus aureus with 
an antiseptic soap and nasal mupirocin among colonized patients – an open uncontrolled 
clinical trial. Ann Clinic Microbiol 2004; 3:9.  
35. Lobbedez T, Gardam M, Dedier H, et al. Routine use of mupirocin at the peritoneal 
catheter exit site and mupirocin resistance: still low after 7 years. Nephrol Dial Transplant 
2004; 19:3140-3. 
36. Mody L, Kauffman CA, McNeil SA, Galecki A, Bradley SF. Mupirocin-based 
decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: 
a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:1467-74. 
37. Muller A, Talon D, Potier A, et al. Use of intranasal mupirocin to prevent methicillin-
resistant Staphylococcus aureus infection in intensive care units. Critical Care 2005; 
9:R246-50. 
38. AHFS Drug Information 2005 p3419-20, 3350-3. 
39. Bactroban® Prescribing Information 
40. Caierao J, Berquo L, Dias C, d’Azevedo PA. Decrease I nthe incidence of mupirocin 
resistance among methicillin-resistant Staphylococcus aureus in carriers from an intensive 
care unit. Am J Infect Control 2006; 34:6-9. 
41. Graham III PL, Lin SX, Larson EL. A US population-based survey of Staphylococcus 
aureus colonization. Ann Intern Med 2006; 144:318-25. 
42. Padoveze MC, Tresoldi AT, vonNowakonski A, et al. Nasal MRSA colonization of 
AIDS patients cared for in a Brazilian University Hospital. Infect control Hosp Epidemiol 
2001; 22:783-5. 
43. Ellis MW, Hospenthal DR, Dooley DP, et al. Natural history of community-acquired 
methicillin-resistant Staphylococcus aureus colonization and infection in soldiers Clin 
Infect Dis. 2004;39:971-979. 
44. Strickland DM, et al.  Vaginal Absorption of Hexachlorophene During Labor.  Am J 
Obstet Gynecol 1983;147:769-72. 
45. Crum-Cianflone NF, Weekes J, Bavaro M. Recurrent Community-Associated MRSA 
Infections among HIV-Infected Persons: Incidence and Risk Factors. AIDS Patient Care 
and STDs, 2009; 23:499-502. 
46. Crum-Cianflone NF, Burgi A, Hale BR. Increasing rates of community-acquired 
MRSA infections among HIV-infected persons.  Int J STD AIDS. 2007;18:521-6. 
 
  
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
34 
 
XVII.   APPENDICES 
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
35 
APPENDIX A: ADVERTISING FLIER 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
36 
APPENDIX B: BUDGET 
 
            
 
BUDGET SUMMARY: STUDY TOTAL (FY2011) 
 
Category 
                       
Total Budget (all sites)  
NMCSD 
 
Minor Equipment                                          ---- 
 
 
---- 
 
Expendable Supplies                                     $6,504  
 
$504 
 
Miscellaneous Expenses                                $6,720  
 
$4,000 
(including printing, reproduction, 
and publication) 
 
Travel (for data presentation)                         ---- 
 
 
---- 
 
MRSA swab costs: 
    
 
   ---- 
 
 
$412 
 
CD4 counts and HIV viral load testing: 
 ---- 
 
 
$412  
 
 
 
Shipping of specimens: 
                        ---- 
 
 
$756 
 
Mupirocin and phisohex medications:            ---- 
 
 
---- 
 
Placebos 
 
 
 
 
---- 
 
 
---- 
 
Indirect Costs  
 
 
 
$1,814  
 
943 
 
TOTAL                                                    
$15,038 
 
$7,027 
 
Funded by the Henry M. Jackson Foundation (HJF) 
The cost of the molecular work is provided by the SAMMC laboratory. Cultures of 
infected wounds and treatment of active infections are considered standard of care and are 
not included in the budget estimate. 
 
 
 
 
 
 
 
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
37 
APPENDIX C:  ROLES AND RESPONSIBILITIES 
 
Designation of Roles and Responsibilities 
 
Principal Investigator (PI):  To promptly report changes or unanticipated problems in a 
research activity.  Normally, changes may not be initiated without OTSG approval, except 
where necessary to eliminate apparent immediate hazards to the human subject or others, 
immediately report, by telephone, any serious or unexpected adverse experiences which 
occur to the human subject or others to the Regulatory Compliance (DSN 343-2165 or 
301-619-2165) (non-duty hours call DSN 343-2165 and send information by facsimile to 
DSN 343-7803 or 301-619-7803). To promptly report any change of investigators. To 
prepare annual continuing review reports at intervals designated by the Uniformed 
Services University of the Health Sciences IRB and to report SAEs to the Uniformed 
Services University of the Health Sciences IRB. 
 
Site Principal Investigators (SPI):  To act as the Principal Investigator for the 
participating site.  To promptly report changes or unanticipated problems in a 
research activity to the PI.  To assist the PI in all aspects of protocol execution. 
 
Laboratory Investigators:  To execute laboratory procedures in compliance with all 
relevant regulatory guidelines inclusive of specimen accession, processing, aliquoting, 
distribution and archiving. 
 
Research Coordinators: To interface with protocol volunteers. To maintain records of 
contact, administer questionnaires, and complete CRFs.  To perform phlebotomy, obtain 
nasal, throat, axilla, groin, and perirectal swabs, prepare and package samples for shipment 
and report directly to the PI.    
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
38 
APPENDIX D: SCHEDULE OF EVENTS 
 
Event 
 
Visit 
1 
Visit 
2 
Visit 
3 
Visit 
4 
Visit 
5 
Positive 
MRSA 
Colonization 
visit 
MRSA 
Colonization 
Follow-up 
visit 
MRSA/Soft 
Tissue 
Infection 
Visit 
Additional / 
Unscheduled 
Visit 
Study Month 
(Window: months) 
0 
6 
(±2) 
12 
(±2) 
18 
(±2) 
24 
(±2) 
 
 
 
 
Informed Consent 
X 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
Criteria 
X 
 
 
 
 
 
 
 
 
Urine Pregnancy 
Test for women of 
childbearing age 
X 
 
 
 
 
X# 
 
X# 
 
Enrollment 
X 
 
 
 
 
 
 
 
 
Questionnaires 
including Medical 
History, 
Medications and 
MRSA Risk 
Factors 
X 
X 
X 
X 
X 
X 
 
X 
 
Demographics 
X 
 
 
 
 
 
 
 
 
MRSA Swabs for 
Colonization 
X 
X 
X 
X 
X 
 
X 
X 
 
Randomization* 
 
 
 
 
 
X 
 
*** 
 
Dispense Drug* 
 
 
 
 
 
X 
 
*** 
 
AE Review*** 
 
 
 
 
 
  
X 
 
X 
Drug 
Accountability 
 
 
 
 
 
  
X 
 
 
CD4 count/HIV 
Viral Load** 
 
 
 
 
 
 
 
X 
 
Wound Culture and 
possibly blood 
cultures**** 
 
 
 
 
 
 
 
X 
 
Study Completion 
 
 
 
 
X 
 
 
 
 
#Pregnancy test will only be performed at the MRSA colonization and infection visits among 
women who found to be colonized with MRSA; those with a positive pregnancy test will not 
receive the study medications and will be terminated from the study. 
*Randomization into the mupirocin (Bactroban®) and hexachlorophene (pHisoHex®) soaps or to 
the placebo arm will only occur if a patient has a positive colonization swab for MRSA.  Patients 
will be randomized in a 1:1 double-blinded fashion into these groups.  Patients with colonization, 
regardless of the group assigned, will have repeat swabs for MRSA performed monthly (+/- 7 days) 
for six consecutive months.  For patients with repeat positive MRSA colonization swabs on the 6-
month visits, will be re-randomized during each of these events. 
**AE review will occur among patients given mupirocin (Bactroban®) and hexachlorophene 
(pHisoHex®) or the placebo ointment and soap.  AE’s will be assessed that are temporally 
associated with study medications. 
***Patients who are also found to have positive colonization swabs in addition to an infection will 
be randomized to one of the two treatment groups if this patient was not already randomized and 
the same procedures for a positive colonization visit will be followed. 
****Patients presenting with a soft tissue infection will have wound cultures obtained if possible.  
Blood cultures also may be obtained at the primary treating physician’s discretion 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
 
39 
 
 
 
XVIII.  ATTACHMENTS 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
40 
 
ATTACHMENT A: TOXICITY TABLE 
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
41 
 
ATTACHMENT B: INFORMED CONSENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
42 
 
ATTACHMENT C: REQUIREMENTS FOR STUDIES INVOLVING HUMAN 
PATIENTS 
 
18.C.1 Study Conduct 
 
The investigator agrees that the study will be conducted according to the principles of Good 
Clinical Practices (GCPs) and the Declaration of Helsinki (1998).  The investigator will conduct 
all aspects of this study in accordance with all national, state, and local laws of the pertinent 
regulatory authorities. 
 
The PI must provide a copy of a current Curriculum Vitae (CV).   
 
18.C.2 Subject Confidentiality 
 
The research will be conducted at Infectious Disease clinics at NMCSD, WRNMMC, SAMHS, 
NMCP among HIV-infected subjects enrolled in those clinics.  These clinics are both 
experienced in the conduct of clinical trials and other research, and are aware of requirements of 
patient privacy.  The study forms will be maintained in locked file cabinets at the respective ID 
clinics.  The data analysis will be done on computers with password-protection.  Electronic data 
transfer will be done on coded data only, and no material with patient identifiers (such as name) 
will be transferred electronically. 
 
The PI will maintain research records at each participation site.  Each subject will be identified 
on study records with a six-digit participant identification number (PIN), to maintain 
confidentiality of study subject participation.  A computer program generates the study number 
randomly.  Only those directly involved in the conduct of the study will have access to subjects’ 
medical records.  In all publication and presentations resulting from this research study, all 
personal information will be kept in the strictest confidence and will not be released in any form 
identifiable to any subject.  However, authorized personnel from the National Institute of Health 
(NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Uniformed Services 
University of the Health Sciences (USUHS), the Tri-Service Investigating Department, 
representatives from the sponsoring agencies, representatives from regulatory agencies, and from 
the Food and Drug Administration (FDA), where applicable, may have access to research files, 
but they are bound by the rules of confidentiality not to reveal subject identities.   
 
18.C.3 Subject Compensation 
 
No compensation will be provided to subjects in this study.   
 
18.C.4 Medical Monitors 
 
Each site will have a qualified Medical Monitor.  The Medical Monitor will be cognizant of the 
medical welfare of the enrolled subjects.  In this capacity he/she will perform the following 
functions to ensure protection from excessive risks: 
a. Monitor the consent process to ensure an absence of coercion 
b. Monitor data collection and clinical outcomes 
c. Be appraised of unexpected and serious adverse event reports 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
43 
d. Make sure inclusion/exclusion criteria are followed by reviewing source 
documentation 
e. Review data security measures 
f. Have full access to study data 
 
The Medical Monitor has the authority to recommend suspension or disenrollment or any other 
steps deemed necessary to protect the research experience. 
 
18.C.5 Experimental Procedure(s) 
 
Administration of the mupirocin (Bactroban®) nasal ointment and hexachlorophene 
(pHisoHex®) soap body washes or a placebo ointment and soap is the only part of the study that 
is experimental.  Patients will also have swabs taken of their nares, throat, axilla, groin and 
perirectal area using a soft q-tip like culture swab. The study may also involve a blood draw for 
CD4 counts and HIV viral load, wound culture of a soft tissue infection, and possibly blood 
cultures if a patient has a MRSA infection or soft tissue infection; when possible the blood tests 
will be obtained at the same time that blood tests ordered by the primary physician are obtained. 
 
18.C.6 Risks 
 
Risks of the study include the administration of FDA-approved medications mupirocin 
(Bactroban®) nasal ointment and hexachlorophene (pHisoHex®) soaps both applied topically) 
for those who are colonized with MRSA and randomized to the treatment group, and a blood 
draw for those who experience a soft tissue or MRSA infection during the study. There are also 
the psychological and legal risks if a subject’s information is accidentally revealed to an 
unauthorized source. 
 
Bactroban® (Mupirocin calcium 2%) is an FDA-approved medication administered intranasally 
for elimination of nasal carriage of Staphylococcus aureus.  Local reactions, such as burning, 
stinging, soreness and pruritis have occurred in 1-2% of patients, but are rarely severe enough to 
result in medication discontinuation.  Irritation of the nasal mucosa is believed to be due to the 
polyethylene glycol vehicle utilized to deliver the drug, which, if applied to damaged skin, may 
result in systemic absorption and renal toxicity.   However, this is unlikely in situations, such as 
in this study, where the agent is applied to small, intact areas of the mucosa.  Avoidance of 
ophthalmic exposure to the nasal formulation is of key importance, as it may result in burning 
and tearing that may take days to weeks to resolve.  Other effects, such as headache, taste 
perversion, rhinitis, pharyngitis, and cough may occur with mupirocin (Bactroban®) nasal 
application [39].  The Food and Drug Administration rates mupirocin (Bactroban®) as a Category 
B drug, with no evidence of fetal harm in rats and rabbits; however, it has not been tested in 
pregnant women to date.   In addition, it is not known whether the drug is excreted in breast 
milk.  Hence, in this study both pregnant and breastfeeding females are excluded.    
 
pHisoHex® (hexachlorophene 3% w/w) is an FDA-approved topical antiseptic agent used 
extensively as a surgical hand scrub and for decolonization of patients who carry gram-positive 
bacteria during outbreaks. The most common side effects of topical hexachlorophene 
(pHisoHex®) are local skin reactions such as dermatitis and photosensitivity.   Rare cases of 
photoallergy have occurred and use of this agent in patients with history of light sensitivity.  
Topical administration can result in systemic absorption especially when applied to abraded skin; 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
44 
patients will receive a medication information sheet recommending the avoidance of applying 
hexachlorophene (pHisoHex®) to areas of abraded skin. This medication is category C in 
pregnancy as large doses of hexachlorophene (pHisoHex®) given orally and intravaginally have 
proven embryotoxic and teratogenic in animal studies.  Although there have been inadequate 
studies in humans, one retrospective review found an increased incidence of fetal malformations 
and minor deformities of children born to nurses washing their hands with hexachlorophene 
(pHisoHex®) 10-60 times daily [38, 44].  The risk of toxicity in this study is low since the soap 
will be only used once daily for seven days among patients found to carry MRSA.  All females 
who become pregnant or plan on becoming pregnant will be excluded from this study. 
 
The placebo ointment which is a white petroleum jelly may cause local reactions, such as 
burning, stinging, soreness and pruritis.  The placebo body soap will not have an antibacterial 
properties; it may cause a local skin reaction such as dermatitis. 
 
The risk of phlebotomy is excess bleeding, bruising, discomfort at the site of puncture, infection, 
and rarely “fainting” (vasovagal syncope).  Phlebotomy is generally considered a minimal risk 
procedure. Blood draws will be obtained at the same time that laboratories ordered by the 
patient’s primary physician are drawn when possible.  Patients will be closely monitored and 
have access to medical care 24 hours a day through the emergency room and Infectious Disease 
clinic. 
   
18.C.7 Benefits 
 
The benefit of the study includes the possibility of detecting MRSA colonization and clearing it 
to prevent infections from this organism.  The risks of blood draws and topical mupirocin 
(Bactroban®) and hexachlorophen (pHisoHex®) soap or placebo ointment and soap are low.  A 
study establishing guidelines on screening and decolonization of MRSA among HIV patients 
could lead to better healthcare and fewer soft tissue and MRSA infections in this population.  
 
18.C.8 Informed Consent 
 
A model informed consent form will be provided to each investigator.  If the model informed 
consent is modified, a copy of the modified form must be provided to the Sponsor by the 
investigator for approval prior to submission to the IRB or EC.  The final informed consent form 
must be approved by the IRB or EC. 
 
Before recruitment and enrollment, each prospective candidate or the candidate’s legally 
authorized representative will be given a full explanation of the study and allowed to read the 
implications of participating in the study, the subject or the representative will be asked to give 
consent to participate in the study by signing the informed consent form.  The investigator will 
provide a copy of the signed informed consent form to the subject or the representative.   
 
 
18.C.9 Institutional Review Board or Ethical Review Committee (IRB or ERC) 
 
Before initiation of the study, the investigator must obtain approval of the research protocol and 
informed consent form from an IRB and/or EC complying with the provisions specified in 45 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
45 
CFR Part 46 or applicable pertinent government regulations.  The investigator must assure IRB 
or ERC compliance with the applicable regulations. 
 
A copy of written IRB or ERC approval of the protocol and informed consent must be provided 
to the Sponsor prior to initiation of the study.  The approval letter must be signed by the IRB or 
ERC chairman or designee, identifing the IRB/ERC name and address, the clinical protocol by 
title and/or protocol number, and the date approval was granted.   
 
The investigator is responsible for obtaining continued review of the clinical research at intervals 
not exceeding one year or otherwise specified by the IRB or ERC.  The investigator must supply 
the Sponsor with the written documentation of continued review of the clinical research. 
 
18.C.10 
Protocol Amendments and Emergency Deviations 
 
Changes to the research covered by this protocol must be implemented by a formal protocol 
amendment.  Amendments to the protocol may be initiated by the Sponsor or at the request of the 
investigator.  In either case, a formal amendment can not be initiated until it has been approved 
by the Sponsor, signed by the investigator and approved by the IRB or ERC. 
 
Emergency deviations or modifications may be initiated without the Sponsor or IRB/ERC 
approval, only in cases where the change is necessary to eliminate an immediate apparent hazard.  
Emergency deviations or modifications must be reported to the Sponsor and the IRB or ERC 
within five business days of the occurrence. 
 
18.C.11 
Monitoring of Study sites by the Sponsor’s Representative 
 
The trial will be conducted in compliance with this protocol, International Conference on 
Harmonization (ICH) Guideline for Good Clinical Practices (GCP) and any applicable regulatory 
requirements(s).  Monitors under contract to the NIAID will visit the clinical research site to 
monitor all aspects of the study in accordance with the appropriate regulations.  The objectives of 
a monitoring visit will be:   
1. To verify the prompt reporting of all data points, including reporting SAEs, checking 
availability of signed informed consent; 
2. To compare individual subjects records, electronic data pulls and the source documents 
(supporting data, laboratory specimen records and medical records to include physician 
progress notes, nurse’ notes, subjects’ hospital charts); and 
3. To ensure protection of study subjects, compliance with the protocol, and accuracy and 
completeness of records.   
 
The monitors also will inspect the clinical site regulatory files to ensure that regulatory 
requirements (OHRP) and guidances (ICH-GCP) are being followed.  During the monitoring 
visits, the investigator (and/or designee) and other study personnel will be available to discuss 
the study progress and monitoring visit.  
 
The investigator (and/or designee) will make study documents (e.g. consent forms, electronic 
data pulls) and pertinent hospital or clinical records readily available for inspection by the local 
IRB, the FDA, the site monitors and the NIAID staff for confirmation of the study data.  
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
46 
18.C.12 
Case Report Forms and Study Records 
 
As part of the responsibilities assumed by participating in the study, the investigator agrees to 
maintain adequate case histories for the patients treated as part of the research under this 
protocol.  The investigator agrees to maintain accurate case report forms and source 
documentation as part of the case histories. 
 
18.C.13 
Laboratory Certification and Normal Ranges 
 
The investigator agrees to provide to the Sponsor with laboratory certification and normal range 
values for any clinical laboratory selected by the investigator to analyze clinical specimens. 
 
18.C.14 
Drug Accountability 
 
The investigator or designated responsible party is responsible for storing the drug in a secure 
location, under conditions described on the label, and for maintaining adequate records of drug 
disposition which includes the dates, quantity, and use by patient.  If the investigation is 
terminated, discontinued, suspended or completed all unused supplies of the drug will be 
returned to the Sponsor, unless other instructions are provided. 
 
The drug will not be dispensed to any person who is not a study subject under this protocol. 
 
18.C.15 
Record Retention 
 
The investigator agrees to retain study records for the time periods stated below. 
 
In the United States, an investigator shall retain records required to be maintained for a period of 
two years following the date a marketing application is approved for the indication for which it is 
being investigated; or, if no application is to be filed or if the application is not approved for such 
indication, until three years (per the NIH MPA) after the investigation is discontinued and the 
FDA is notified. 
 
18.C.16 
Inspection of Records 
 
In the event of an inspection, the investigator agrees to allow representatives of the Sponsor, the 
National Institute of Health or other regulatory agency access to all study records. 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
47 
ATTACHMENT D: PACKAGE INSERTS 
 
Mupirocin calcium 2% (Bactroban®) and Hexachlorophene 3% w/w (pHisoHex®) 
 
 

Prospective MRSA Study 
Version 7.0 
July 2, 2014 
 
48 
 
 
 
 
ATTACHMENT E: PROTOCOL SIGNATURE PAGE 
 
Principal Investigator Signature Page 
 
I agree to conduct this clinical trial according to the protocol described herein, except when 
mutually agreed to in writing.  I also agree to conduct this study in compliance with all 
applicable regulations, as well as with the requirements of the appropriate Institutional Review 
Board and any other institutional requirements.  This protocol is designed and will be conducted, 
documented and reported in compliance with Good Clinical Practice (GCP). These guidelines 
are stated in the US federal regulations. I have read and agree to abide by the requirements of 
this protocol. 
 
Principal Investigator 
 
 
_____________________________________________ 
Signature 
Printed Name                    Date